INTRODUCTION AND OBJECTIVES: Potent androgen receptor inhibitor enzalutamide (ENZA) provides benefit in men with castration-resistant prostate cancer (CRPC). ARCHES, a multinational, double-blind, placebo (PBO)-controlled, Phase 3 study (NCT02677896), examined the efficacy of ENZA with androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC). As an important marker of prostate cancer, here we report prostate-specific antigen (PSA) results for ARCHES.
METHODS: Patients (pts) with mHSPC were randomized 1:1 to ENZA (160 mg/day) þ ADT or PBO þ ADT, stratified by disease volume and prior docetaxel. Up to 3 months of ADT ( 6 months if with docetaxel) with no radiographic disease progression or rising PSA levels prior to day 1 was allowed. The primary endpoint was radiographic progression-free survival (rPFS) [scans assessed centrally] or death within 24 weeks of treatment discontinuation. Pre-specified analyses included rPFS (overall and by baseline PSA levels), time to PSA progression, time to castration resistance, PSA undetectable rate, and PSA reduction from baseline. Treatment continued until disease progression or unacceptable toxicity.
RESULTS: 1150 pts were randomized (ENZA þ ADT, n[574; PBO þ ADT, n[576). Baseline characteristics were balanced between groups; 91% had prior ADT. Overall median baseline PSA level was 5.21 ng/mL; median follow-up was 14.4 months. ENZA þ ADT significantly improved rPFS overall, regardless of baseline PSA level (Table) . ENZA þ ADT significantly improved time to PSA progression and time to castration resistance. The proportions of pts with undetectable PSA or PSA reduction !50% or !90% from baseline during the study were higher with ENZA þ ADT. Adverse events were reported in 85.1% of ENZA þ ADT pts vs 85.9% of PBO þ ADT pts, with no unexpected adverse events.
CONCLUSIONS: ENZA þ ADT significantly improved rPFS vs PBO þ ADT in pts with mHSPC, regardless of baseline PSA level, suggesting the limitation of baseline PSA as a predictive factor in this population in which most pts received prior ADT. However, ENZA þ ADT significantly improved PSA-related efficacy endpoints. Preliminary safety analysis appears consistent with the safety profile of ENZA in previous CRPC clinical trials.
Source of Funding: This study was funded by Astellas Pharma Inc. and Medivation LLC, a Pfizer Company, the co-developers of enzalutamide. Medical writing and editorial assistance were provided by Caitlin Watson and Lauren Smith from Complete HealthVizion, funded by the study sponsors.
LBA-11 PAIREDCAP TRIAL: PROSPECTIVE ASSESSMENT OF IMAGE REGISTRATION IN DIAGNOSIS OF PROSTATE CANCER
Rajiv Jayadevan*, Fuad Elkhoury, Ely Felker, Lorna Kwan, Anthony Sisk, Merdie Delfin, Shyam Natarajan, Leonard Marks, Los Angeles, CA INTRODUCTION AND OBJECTIVES: Herein is presented final results of a paired-cohort trial (PAIREDCAP), in which cancer-detection rates (CDR) of software-targeted, cognitive-targeted, and systematic biopsies are compared, with each man serving as his own control. Such data are lacking and may help direct future use of MRI-guided biopsy.
METHODS: Subjects were 300 men undergoing first-time prostate biopsy. A powered sample of 248 consecutive men with MRI-visible lesions (PIRADS v2 ! 3) underwent all 3 biopsy methods at the same session: first, 12-core systematic biopsy; second, MRIlesion targeted cognitively; third, MRI-lesion targeted by software fusion. Most lesions were PIRADS Grade 4 or 5 (192/248, 78%); 38% were anterior. A comparison group of 52 men with negative mpMRI underwent systematic biopsy only. The primary endpoint was CDR of clinically significant prostate cancer (csCaP: Gleason ! 3þ4).
RESULTS: In the paired cohort, CDR was 47% for cognitive targeting, 60% for systematic sampling, and 62% for software targeting. The overall CDR was 70% (178/248) when systematic and targeting methods were combined. 11%-33% of cases would have been missed by using a single biopsy method. CDR was directly related to PIRADS grade (grade 3, 23%; grade 4, 64%; and grade 5, 80% p<0.01). Men with PSA density (PSAD) ! 0.15 had a three-fold risk of csCaP as those with PSAD <0.10. Within PIRADS grades and PSAD strata, CDR was similar between biopsy methods. CDR was 15% (8/52) in patients with negative MRI. Among 38 men with a negative MRI and a PSAD <0.15, only 3 (8%) had csCaP. In a post-hoc analysis of tumor locations, a discordance of 36% was found between targeted and systematic biopsies, indicating that different tumors were detected by each method (Table 1) .
CONCLUSIONS: In men with MRI-visible lesions, the combination of systematic and targeted biopsy maximizes csCaP detection (70% vs 47-62% with either method alone). Data from this paired-cohort trial provide high-level evidence that MRI guidance is of value in men undergoing a first prostate biopsy.
